MedTrace Logo

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

NCT00704691 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2012-04-20

No results posted yet for this study

Summary

The purpose of this study is to:

* assess the effectiveness of lenalidomide for the treatment of patients with relapsed and or refractory peripheral T-cell lymphomas; and,
* assess the safety of lenalidomide.

There are reports suggesting a therapeutic benefit of thalidomide in patients with refractory and/or relapsed Non-Hodgkin's Lymphoma's (NHL) which have led to the formal investigation of lenalidomide in the treatment of relapsed NHL's.

Conditions

  • Peripheral T-cell Lymphomas
  • Adult T-cell Leukemia
  • Adult T-cell Lymphoma
  • Peripheral T-cell Lymphoma Unspecified
  • Angioimmunoblastic T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • T/Null Cell Systemic Type
  • Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease

Interventions

DRUG

Lenalidomide

Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • James Foran, M.D. · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-07-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704691 on ClinicalTrials.gov